In a surprising clinical trial, a common hay fever nasal spray significantly reduced COVID-19 infections, offering an unexpected tool against the virus.
Story Overview
- Azelastine nasal spray reduced COVID-19 infections by 69% in a clinical trial.
- The study was conducted at Saarland University Hospital in Germany.
- This nasal spray is already available over the counter for allergies.
- Larger trials are needed to confirm these findings for broader application.
Clinical Trial Findings on Azelastine Nasal Spray
In a phase 2 randomized, double-blind clinical trial at Saarland University Hospital in Germany, researchers discovered that the antihistamine nasal spray azelastine reduced the risk of PCR-confirmed COVID-19 infections by approximately two-thirds compared to a placebo. The trial, which enrolled participants between March 2023 and July 2024, found that the nasal spray was also effective against rhinovirus infections, suggesting its potential as an accessible, low-cost preventive measure against respiratory viruses.
The trial’s results, published in September 2025 in *JAMA Internal Medicine*, have sparked interest due to the spray’s affordability and availability. Azelastine, which has been approved for allergic rhinitis for decades, demonstrated antiviral activity against SARS-CoV-2 in vitro early in the pandemic. Now, this real-world efficacy could position azelastine as a supplementary tool alongside traditional public health measures like vaccination.
Potential Implications and Next Steps
The trial’s success opens the door to new public health strategies, especially in enhancing protection during periods of high virus transmission. However, researchers emphasize that azelastine should not replace vaccinations or other established preventive measures. They advocate for larger, multicenter trials to validate these findings and explore broader applications. If confirmed, azelastine could be incorporated into guidelines as a low-cost prophylactic against respiratory viruses, potentially easing healthcare burdens in future pandemics.
Experts caution that while promising, these results should be viewed as a complement to, not a replacement for, existing health protocols. The nasal spray’s availability over the counter could foster greater public access, particularly in regions with limited healthcare resources. However, regulatory bodies will need to review and possibly update guidelines to reflect these new findings, potentially influencing public health policy and pandemic preparedness strategies.
Community and Economic Impact
The broader implications of this finding could be significant. Economically, using azelastine could reduce healthcare costs by preventing infections, potentially increasing sales for pharmaceutical manufacturers. Socially, it provides a more accessible preventive measure, especially in low-resource settings. Politically, it may prompt discussions on integrating such cost-effective solutions into national health strategies.
For the pharmaceutical industry, these findings may stimulate further research into repurposing existing medications for infectious disease prevention. This could lead to a surge in interest and investment in similar studies, driving innovation within the sector.
Sources:
PubMed (JAMA Internal Medicine)
